Pharma Journalist -

Pfizer asserted that the Committee for Medicinal Products for human use of the European Medicines Agency has disapproved of expanding use of SUTENT to encompass the adjuvant treatment…
Read More...

CEL-SCI Corporation asserted that it was extending the expiration date of its Series DD and Series EE warrants to July 1, 2018. The Series DD and Series EE warrants were issued on…
Read More...

Hong Kong based investment firm, PacBridge Capital Partners has committed to invest C$12,000,000 in Contextual Genomics, leading Canadian Cancer genomics company headquartered in…
Read More...

Pfizer asserted that that the Committee for Medicinal products for Human use of the European Medicines Agency has adopted positive opinions extending marketing authorizations in the EU…
Read More...

BPI Europe Summit, THE Bioprocessing event, bringing together key players from all major departments in bioprocessing: Cell Culture, Downstream, Manufacturing, Vaccines, Viral Safety…
Read More...

AstraZeneca asserted that the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the…
Read More...

NaviGate Cardiac Structures asserted that its catheter-guided GATE valved-stent bioprosthesis became the first Canadian orthotopic valve replacement to treat severe tricuspid…
Read More...

Clovis Oncology claimed an update to the ongoing regulatory review for the Marketing Authorization Application (MAA) for Rucaparib tablets as monotherapy for the treatment of advanced…
Read More...

Merck and Viralytics claimed that the companies have ventured into a definitive agreement that enumerates Merck's acquisition of Viralytics emphasizing on oncolytic immunotherapy…
Read More...

Celgene Corporation asserted that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender…
Read More...